CSIMarket Company Name, Ticker, Industry, else..
 
Biodesix Inc   (NASDAQ: BDSX)
Other Ticker:  
 
    Sector • Healthcare    Industry • Medical Laboratories
   Industry • Medical Laboratories
   Sector • Healthcare
 
Price: $1.0300 $0.13 14.381%
Day's High: $1.05 Week Perf: -10.43 %
Day's Low: $ 0.90 30 Day Perf: -34.39 %
Volume (M): 483 52 Wk High: $ 2.21
Volume (M$): $ 497 52 Wk Avg: $1.54
Open: $0.90 52 Wk Low: $0.86



 Market Capitalization (Millions $) 151
 Shares Outstanding (Millions) 146
 Employees 55
 Revenues (TTM) (Millions $) 66
 Net Income (TTM) (Millions $) -44
 Cash Flow (TTM) (Millions $) 12
 Capital Exp. (TTM) (Millions $) 5

Biodesix Inc
Biodesix Inc is a molecular diagnostics company that specializes in the development and commercialization of diagnostic tests for various diseases, including cancer. The company focuses on personalized medicine, aiming to provide physicians with actionable information that can help in making treatment decisions for their patients. Biodesix offers a range of tests that utilize advanced technology platforms to analyze genetic and proteomic biomarkers with the goal of improving patient outcomes. Their innovative diagnostic tests are designed to enable early disease detection, treatment monitoring, and prediction of disease progression.


   Company Address: 919 West Dillon Rd Louisville 80027 CO
   Company Phone Number: 417-0500   Stock Exchange / Ticker: NASDAQ BDSX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EXAS      % 
GH      % 
NTRA      % 
PSNL      % 
VCYT      % 
PMVP      % 
• View Complete Report
   



Business Update

Biodesix Breaks Ground at CHEST 2024, Yet Faces Market Headwinds

Published Mon, Oct 7 2024 10:47 AM UTC

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study In a bold maneuver that showcases its commitment to advancing lung disease diagnostics, Biodesix, Inc. (Nasdaq: BDSX) is set to make waves at the highly anticipated CHEST Annual Meeting 2024 in Boston, Massachusetts. On Tuesday, October 8, at 10:20 am ET, th...
Business Update

Revamping Lung Disease Diagnosis: Biodesix Unveils Promising Breakthrough at ATS 2024 Annual Meeting

Published Tue, May 21 2024 10:47 AM UTC

Biodesix, Inc. (Nasdaq: BDSX), a pioneering diagnostic solutions company specializing in lung disease, has recently announced ground-breaking new data that will be presented at the 2024 American Thoracic Society (ATS) International Conference. The data will demonstrate the success of Biodesix s Nodify XL2 Test in accurately stratifying lung nodule risk in patients with and w...
Business Update

Biodesix's Lung Diagnostic Testing Powers Impressive Revenue and Volume Growth in Q1 2024, Reinforcing Commitment to Patients' Well-being.

Published Thu, May 9 2024 2:24 AM UTC

Biodesix Announces Impressive First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule ManagementLOUISVILLE, Colo. - Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company specializing in lung disease, has reported its financial and operating results for the first quarter ended March 31, 2024. The company s performance during this...
Biodesix Inc

Biodesix Inc Surges Towards Profitability With Remarkable Q3 2023 Performance

Biodesix Inc, a leading provider of diagnostic solutions for lung diseases, has shown impressive improvement in its financial performance for the third quarter of 2023. The company reported a decrease in loss per share, with a significant improvement from $-0.34 per share in the same quarter a year ago to $-0.14 per share. Additionally, the company's earnings per share (EPS) improved from $-0.17 per share in the preceding quarter. These positive results indicate that Biodesix Inc is moving in the right direction and making strides towards profitability.
One of the key factors contributing to Biodesix Inc's positive performance is its revenue growth. The company witnessed a rapid increase in revenue of 21.464% to $13.49 million, compared to $11.11 million in the same quarter a year ago. Sequentially, the revenue also advanced by 13.637% from $11.87 million in the previous quarter. These impressive growth figures highlight the company's ability to attract more customers and generate higher sales.
Biodesix Inc

BDSX Gaining Financial Stability; Deficit Significantly Reduces in Q2 2023

During the past 5 trading days, Biodesix Inc's stock experienced a significant drop of -10.83%. This decline contributes to the year-to-date performance, which now stands at -47.8%. Additionally, the stock currently trades 12% above its 52-week low. These statistics may be concerning for investors and warrant further analysis of the company's financial performance and industry outlook.
Looking at the financial results for the April to June 2023 time-frame, Biodesix Inc showed signs of improvement compared to the previous year. The loss per share decreased from $-0.40 to $-0.17, indicating progress in managing expenses. Moreover, the income per share also improved, moving from $-0.24 to an undisclosed positive value, which is a positive development for the company.






Biodesix Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com